)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Vigil Neuroscience
Vigil Neuroscience (VIGL) investor relations material
Vigil Neuroscience has been acquired by Sanofi
Vigil Neuroscience Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary5 Aug, 2025
Executive summary
Entered definitive merger agreement with Sanofi; shareholders to receive $8.00 per share in cash plus a $2.00 contingent value right tied to VG-3927 commercialization; merger expected to close in Q3 2025.
Phase 2 IGNITE trial for iluzanebart in ALSP discontinued after no efficacy observed; VG-3927 Phase 1 data showed favorable safety and PK/PD profile for Alzheimer's disease.
As of June 30, 2025, cash, cash equivalents, and marketable securities totaled $67.0 million; accumulated deficit reached $356.1 million.
Company expects to continue incurring significant losses and will require additional funding if the merger does not close.
Financial highlights
Net loss for Q2 2025 was $26.7 million, compared to $21.2 million in Q2 2024; net loss for the six months ended June 30, 2025 was $49.1 million, up from $41.2 million year-over-year.
Research and development expenses for Q2 2025 were $17.4 million, up from $15.5 million in Q2 2024; general and administrative expenses rose to $10.1 million from $6.9 million.
Interest income declined to $0.8 million in Q2 2025 from $1.3 million in Q2 2024 due to lower cash balances.
Cash used in operating activities for the first half of 2025 was $44.4 million; net cash provided by financing activities was $13.5 million, primarily from ATM equity sales.
Outlook and guidance
Cash runway expected to fund operations into 2026; substantial doubt exists about ability to continue as a going concern without additional capital or successful merger.
Ongoing focus on advancing VG-3927 for Alzheimer's disease and expanding the microglia-targeted pipeline.
If the merger with Sanofi is not completed, additional funding will be sought through equity, debt, or strategic transactions.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Vigil Neuroscience
- Phase II readouts for TREM2-targeted therapies in ALSP and Alzheimer's expected in 2024.VIGL
Stifel 2025 Virtual CNS Forum - Advancing microglia-targeted therapies with pivotal ALSP and Alzheimer's trial milestones ahead.VIGL2024 Cantor Fitzgerald Global Healthcare Conference
- Promising biomarker-driven neurodegeneration therapies advance toward pivotal data and regulatory milestones.VIGLGuggenheim Securities Inaugural Healthcare Innovation Conference
- Promising TREM2-targeted therapies advance in ALSP and Alzheimer's, with pivotal data ahead.VIGLJefferies London Healthcare Conference 2024
- Phase II ALSP readout in H1 2025 and strong cash position support advancing TREM2 programs.VIGLStifel 2024 Healthcare Conference
- Advancing microglia-targeted neurodegeneration therapies with strong clinical and financial momentum.VIGLH.C. Wainwright 26th Annual Global Investment Conference 2024
- Promising microglia-targeted therapies advance with strong biomarker data and extended cash runway.VIGLMorgan Stanley 22nd Annual Global Healthcare Conference
- Advancing microglia-targeted therapies for ALSP and Alzheimer's with key data expected in 2024.VIGLGoldman Sachs 45th Annual Global Healthcare Conference
- Upcoming data for TREM2 therapies in ALSP and Alzheimer's highlight safety and innovation.VIGLJefferies 2024 Global Healthcare Conference
- Advancing TREM2-targeted therapies with robust biomarker data and key milestones ahead.VIGLGuggenheim SMID Cap Biotech Conference
Vigil Neuroscience
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Vigil Neuroscience, Inc. is a clinical-stage biotechnology company focusing on developing treatments for both rare and common neurodegenerative diseases. The company aims to enhance the function of microglia, which are critical immune cells in the brain, to combat these diseases. Vigil Neuroscience's approach involves using precision medicine to develop targeted drug candidates, particularly focusing on the triggering receptor expressed on myeloid cells 2 (TREM2). Their drug development programs are centered on activating TREM2 to address conditions associated with microglial dysfunction, such as Alzheimer's disease. The company is headquartered in Watertown, Massachusetts, and its shares are listed on the NASDAQ.